2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
March 01 2024 - 6:00AM
Business Wire
2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth
quarter and full year 2023 financial results on Tuesday, March 5,
2024. A conference call and webcast will be held at 8:00 a.m.
ET.
Members of the management team will also be presenting at the
following upcoming investor conferences:
- TD Cowen 44th Annual Healthcare Conference in Boston, MA on
Wednesday, March 6, 2024 at 2:10 p.m. ET
- Leerink Partners Global Biopharma Conference in Miami, FL on
Wednesday, March 13 at 8:00 a.m. ET
Live webcasts of the investor conference presentations will be
available via the Investors and Media section of 2seventy bio’s
website at https://ir.2seventybio.com/. Replays will be archived on
2seventy bio’s site for 30 days following the event.
Earnings Call Information
2seventy bio will host a conference call and live webcast on
March 5, at 8:00 a.m. ET to discuss fourth quarter 2023 / full year
2023 financial results and recent business highlights. To join the
live conference call, please register at:
https://register.vevent.com/register/BI1f96356c45184868a0cde91b2864ffd8.
Upon registering, each participant will be provided with call
details and access codes. The live webcast may be accessed by
visiting the event link at:
https://edge.media-server.com/mmc/p/3ob85kez/.
A replay of the webcast may be accessed from the “News and
Events” page in the Investors and Media section of the Company’s
website at https://ir.2seventybio.com/ and will be available for 30
days following the event.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME.
Cancer rips time away, and our goal is to work at the maximum speed
of translating human thought into action – 270 miles per hour – to
give the people we serve more time. With a deep understanding of
the human body’s immune response to tumor cells and how to
translate cell therapies into practice, we’re applying this
knowledge to deliver the first FDA-approved CAR T cell therapy for
multiple myeloma. We are focused on delivering therapies that are
designed with the goal to “think” smarter and faster than the
disease. Importantly, we remain focused on accomplishing these
goals by staying genuine and authentic to our “why” and keeping our
people and culture top of mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (formerly Twitter) and
LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240301891782/en/
Investors: Elizabeth Pingpank Hickin, 860-463-0469
Elizabeth.pingpank@2seventybio.com Media: Jenn Snyder,
617-448-0281 Jenn.snyder@2seventybio.com
2seventy bio (NASDAQ:TSVT)
Historical Stock Chart
From Oct 2024 to Nov 2024
2seventy bio (NASDAQ:TSVT)
Historical Stock Chart
From Nov 2023 to Nov 2024